Ocugen, Inc. Files 2023 Annual Report on Form 10-K

Ticker: OCGN · Form: 10-K · Filed: Apr 16, 2024 · CIK: 1372299

Ocugen, INC. 10-K Filing Summary
FieldDetail
CompanyOcugen, INC. (OCGN)
Form Type10-K
Filed DateApr 16, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Ocugen, Financial Report, Biopharmaceutical, Net Loss

TL;DR

<b>Ocugen, Inc. reported a net loss of $108.7 million and $1.1 million in total revenues for fiscal year 2023, with R&D expenses decreasing year-over-year.</b>

AI Summary

Ocugen, Inc. (OCGN) filed a Annual Report (10-K) with the SEC on April 16, 2024. Ocugen reported a net loss of $108.7 million for the fiscal year ended December 31, 2023. Total revenues for the fiscal year 2023 were $1.1 million. Research and development expenses decreased to $68.4 million in 2023 from $89.7 million in 2022. General and administrative expenses were $38.8 million for the year ended December 31, 2023. The company had cash and cash equivalents of $111.5 million as of December 31, 2023.

Why It Matters

For investors and stakeholders tracking Ocugen, Inc., this filing contains several important signals. The filing details Ocugen's financial performance and operational status, providing investors with a comprehensive overview of the company's progress and challenges in its biopharmaceutical endeavors. Key financial metrics such as net loss, revenue, and R&D spending are disclosed, offering insights into the company's burn rate and investment in its product pipeline.

Risk Assessment

Risk Level: medium — Ocugen, Inc. shows moderate risk based on this filing. The company reported a significant net loss of $108.7 million for the fiscal year 2023, indicating substantial ongoing investment and operational costs without commensurate revenue generation.

Analyst Insight

Investors should monitor Ocugen's cash burn rate and progress in its clinical trials, particularly for its COVID-19 vaccine candidate, given the substantial net loss reported.

Financial Highlights

revenue
1.1 million
net Income
-108.7 million
cash Position
111.5 million

Key Numbers

Key Players & Entities

FAQ

When did Ocugen, Inc. file this 10-K?

Ocugen, Inc. filed this Annual Report (10-K) with the SEC on April 16, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Ocugen, Inc. (OCGN).

Where can I read the original 10-K filing from Ocugen, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Ocugen, Inc..

What are the key takeaways from Ocugen, Inc.'s 10-K?

Ocugen, Inc. filed this 10-K on April 16, 2024. Key takeaways: Ocugen reported a net loss of $108.7 million for the fiscal year ended December 31, 2023.. Total revenues for the fiscal year 2023 were $1.1 million.. Research and development expenses decreased to $68.4 million in 2023 from $89.7 million in 2022..

Is Ocugen, Inc. a risky investment based on this filing?

Based on this 10-K, Ocugen, Inc. presents a moderate-risk profile. The company reported a significant net loss of $108.7 million for the fiscal year 2023, indicating substantial ongoing investment and operational costs without commensurate revenue generation.

What should investors do after reading Ocugen, Inc.'s 10-K?

Investors should monitor Ocugen's cash burn rate and progress in its clinical trials, particularly for its COVID-19 vaccine candidate, given the substantial net loss reported. The overall sentiment from this filing is neutral.

Key Dates

Filing Stats: 4,422 words · 18 min read · ~15 pages · Grade level 16.1 · Accepted 2024-04-16 15:45:48

Key Financial Figures

Filing Documents

FORWARD LOOKING STATEMENTS

FORWARD LOOKING STATEMENTS Part I Item 1.

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 32 Item 1B. Unresolved Staff Comments 79 Item 1C. Cybersecurity 79 Item 2.

Properties

Properties 80 Item 3.

Legal Proceedings

Legal Proceedings 80 Item 4. Mine Safety Disclosures 80 Part II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 81 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 82 Item 7A .

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 92 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 92 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 92 Item 9A.

Controls and Procedures

Controls and Procedures 92 Item 9B. Other Information 93 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 93 Part III Item 10. Directors, Executive Officers and Corporate Governance 94 Item 11.

Executive Compensation

Executive Compensation 94 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 94 Item 13. Certain Relationships and Related Transactions, and Director Independence 94 Item 14. Princip al Accountant Fees and Services 94 Part IV Item 15. Exhibit and Financial Statement Schedules 95 Item 16. Form 10-K Summary 99

Signatures

Signatures Consolidated Financial Statements F- 1 Unless the context otherwise requires, references to the "Company," "we," "our," or "us" in this report refer to Ocugen, Inc. and its subsidiaries, and references to "OpCo" refer to Ocugen OpCo, Inc., the Company's wholly owned subsidiary. i Table of Contents EXPLANATORY NOTE General Ocugen, Inc. (the "Company") is filing this Annual Report on Form 10-K for the fiscal year ended December 31, 2023. This Form 10-K contains our audited financial statements for the year ended December 31, 2023, and restates certain financial information and related footnote disclosures in the Company's previously issued audited financial statements included in the Company's 2022 Annual Report on Form 10-K as well as unaudited interim financial statements included in the Company's Quarterly Reports on Forms 10-Q for each of the quarterly and year to date periods ended September 30, 2022, June 30, 2022, March 31, 2022, September 30, 2023, June 30, 2023, and March 31, 2023 (collectively, the "Previously Issued Financial Statements"). Background of Restatement On April 1, 2024, the Audit Committee (the "Audit Committee") of the Company's Board of Directors, after discussion with senior management and the Company's independent registered public accountants, concluded that the Company's Previously Issued Financial Statements should be restated and no longer relied upon due to the Company not appropriately accounting for the estimated non-cash consideration and expense in its collaboration arrangements. The financial information that had been previously filed or otherwise reported for the Previously Issued Financial Statements is superseded by the information in this Form 10-K, and should no longer be relied upon. Similarly, any previously issued or filed reports, earnings releases, and investor presentations or other communications describing the Company's financial statements and other related financial information covering th

Business

Item 1. Business. OVERVIEW We are a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. Our technology pipeline includes: Modifier Gene Therapy Platform — Based on the use of nuclear hormone receptors ("NHRs"), we believe our modifier gene therapy platform has the potential to address many retinal diseases, including rare diseases such as retinitis pigmentosa ("RP") (OCU400) and Leber congenital amaurosis ("LCA") (OCU400), with a gene-agnostic approach. We also believe our modifier gene therapy platform has the potential to address many retinal diseases, including a multifactorial dry age-related macular degeneration ("dAMD") using OCU410, which we believe has the potential to treat millions of patients, and Stargardt disease (OCU410ST), which is also a rare disease. We received clearance from FDA to initiate a Phase 3 trial for OCU400 for the treatment of RP and intend to begin dosing patients in 2Q, 2024. We further expect to expand OCU400 Phase 3 development in LCA patients in the second half of 2024 based on Phase 1/2 study results in LCA patients and subject to alignment with the FDA. Currently both OCU410, for the treatment of geographic atrophy ("GA") patients, and OCU410ST, for the treatment of Stargardt patients, programs are in Phase 1/2 clinical development. Novel Biologic Therapy for Retinal Diseases — OCU200 is a novel fusion protein consisting of two human proteins, tumstatin and transferrin. OCU200 possesses unique features which potentially enable it to treat vascular complications of diabetic macular edema ("DME"), diabetic retinopathy ("DR") and wet AMD. Tumstatin is the active component of OCU200 and binds to integrin receptors, which play a crucial role in disease pathogenesis. Transferrin is expected to facilitate the targeted delivery of tumstatin into the retina and choroid and potentially help increase

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing